OTC Watch

All stocks / BTAIQ

BioXcel Therapeutics, Inc. BTAIQ

BioXcel Therapeutics (BTAIQ): shares outstanding up 115% in a year and the latest annual figures in plain language. Each fact links to its SEC filing.

DilutionEstimated float Pink LimitedConnecticut, USA
Live quote on OTC Markets

Market listing

Full name
BIOXCEL THERAPEUTICS INC
Market tier
OTC Pink Limited
Trading status
Active
Last trade
Nov 16
Website
www.bioxceltherapeutics.com
Source: Stockwatch, 2026-11-17

News headlines

BioXcel Therapeutics Enters Into Asset Sale Agreement with Teva Pharmaceuticals
2026-08-28 06:00 · News Release
BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meeting
2026-05-28 07:00 · News Release
BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
2026-05-15 07:00 · News Release
BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI(TM) in the At-Home Setting
2026-04-17 07:00 · News Release
BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions
2026-04-08 07:00 · News Release
BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI(TM) in the At-Home Setting
2026-04-01 07:00 · News Release
BioXcel Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMI(TM) Approval in Outpatient Setting
2026-03-27 07:00 · News Release
BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering
2026-03-11 16:20 · News Release
BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct Offering
2026-03-10 14:36 · News Release
BioXcel Therapeutics Announces Positive Phase 2 Topline Results from Columbia University-Led Study of BXCL501 for Treatment of Opioid Withdrawal
2026-03-05 07:00 · News Release
Headlines only, with links to the full item. Company press releases are written by the company.

The financial report, and what it means

Annual figures to 2025-12-31
The report says
Revenue
$642,000
Net loss
($69,897,000)
What it means

It spends more than it earns

Under strain

Customers paid it $642,000 in the year. It lost $69.9 million. For every $1 that came in, about $109.87 went out.

The report says
Cash and cash equivalents
$28,415,000
Net cash used in operating activities
($57,615,000)
What it means

The cash could run out soon

Under strain

It had $28.4 million in the bank and used about $4.8 million a month. At that pace the money lasts about 6 months unless it borrows or sells more shares.

The report says
Total assets
$44,916,000
Total liabilities
$140,379,000
What it means

It owes more than it owns

Under strain

Everything the company owns adds up to $44.9 million. Its debts and unpaid bills add up to $140.4 million. That is about $3.13 owed for every $1 owned.

What this adds up to

3 of 3 checks show strain. It spends more than it earns. The cash could run out soon. It owes more than it owns. These are facts from the company's own reports, not a recommendation.

Signals

Dilution2026-08-11

Shares outstanding rose from 14,556,743 (2025-08-11) to 31,305,499 (2026-08-11), up 115%.

Rule: Shares outstanding up 20% or more in 12 months. Source record

Estimated float2026-08-11

Estimated float about 31,156,299 shares as of 2026-08-11: 31,305,499 outstanding minus 149,200 held by 4 reporting insider(s).

Rule: Estimated: shares outstanding minus the latest holdings insiders reported on Forms 3/4/5. Holders of 5% or more (13D/13G) are not yet subtracted. Source record

Shares outstanding

Source: SEC filings
2025-09-30
20.0M
2025-11-11
21.9M
2025-12-31
22.3M
2026-03-26
27.1M
2026-03-31
27.1M
2026-05-14
30.9M
2026-06-30
31.3M
2026-08-11
31.3M

Price chart

Chart by TradingView. We do not store or publish prices. Live quote on OTC Markets

Recent filings

2026-10-30 8-KFORM 8-K
2026-09-01 8-KFORM 8-K
2026-08-28 8-KFORM 8-K
2026-08-25 8-KFORM 8-K
2026-08-24 8-KFORM 8-K
2026-08-14 SCHEDULE 13G/A
2026-08-14 3OWNERSHIP DOCUMENT
2026-08-14 4OWNERSHIP DOCUMENT
2026-08-13 10-Q10-Q
2026-08-11 8-KFORM 8-K
2026-08-03 8-KFORM 8-K
2026-07-06 8-KFORM 8-K

Common questions about BTAIQ

Does BTAIQ file reports with the SEC?

Yes. BioXcel Therapeutics files with the SEC under company number 0001720893. The most recent filing we hold is a 8-K dated 2026-10-30.

Source record

How many BTAIQ shares are outstanding?

31,305,499 shares as of 2026-08-11, as reported to the SEC. That is up 115% from 14,556,743 on 2025-08-11.

Source record

Has BTAIQ filed reports late?

We found no late-filing notices (NT 10-K or NT 10-Q) in its last 12 months of SEC filings.

Who runs BioXcel Therapeutics?

Officers named in its insider filings: Vimal Mehta (CEO and President), Javier Rodriguez (See Remarks) and Richard I Steinhart (Chief Financial Officer).

Source record

Is BioXcel Therapeutics making money?

Customers paid it $642,000 in the year. It lost $69.9 million. For every $1 that came in, about $109.87 went out. (Annual figures to 2025-12-31. Facts from the company's own report, not a recommendation.)

Source record